|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:esketamine
|
|
gptkbp:administeredBy
|
REMS program
|
|
gptkbp:approvalYear
|
2019
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:N06AX27
|
|
gptkbp:brand
|
gptkb:Spravato
|
|
gptkbp:CASNumber
|
gptkb:33643-46-8
|
|
gptkbp:chemicalFormula
|
C13H16ClNO.HCl
|
|
gptkbp:contraindication
|
intracerebral hemorrhage
aneurysmal vascular disease
|
|
gptkbp:controlledSubstanceSchedule
|
gptkb:Schedule_III_(US)
|
|
gptkbp:developedBy
|
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:halfLife
|
7-12 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
esketamine hydrochloride
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
NMDA receptor antagonist
|
|
gptkbp:molecularWeight
|
274.19 g/mol
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:PubChem_CID
|
123596
|
|
gptkbp:relatedTo
|
gptkb:ketamine
|
|
gptkbp:routeOfAdministration
|
intranasal
|
|
gptkbp:sideEffect
|
nausea
dizziness
dissociation
sedation
increased blood pressure
|
|
gptkbp:UNII
|
U3G4O2I8YK
|
|
gptkbp:usedFor
|
gptkb:major_depressive_disorder
treatment-resistant depression
|
|
gptkbp:bfsParent
|
gptkb:Spravato
|
|
gptkbp:bfsLayer
|
8
|